Overview

A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

An open-label, single arm, non-randomized, single stage phase II study. 3 phases:Baseline, treatment/duration and Follow-up. All patients will be treated with RAD001 10 mg daily dose until disease progression or unacceptable toxicity death, or discontinuation from the study, for any other reason

Phase:

Phase 2

Details

Lead Sponsor:

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Treatments:

Everolimus
Sirolimus